JPMorgan raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $48 from $45 and keeps a Neutral rating on the shares. The firm updated the company’s model to reflect higher Amvuttra estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals doses first patient in REVEAL study
- Ionis Pharmaceuticals Holds Annual Stockholders Meeting
- Ionis Pharmaceuticals: Buy Rating Affirmed Amid Promising Clinical Trial Results and Future Prospects
- Cautious Optimism for Ionis Pharmaceuticals Amid Promising Olezarsen Data and Awaited CORE/CORE2 Insights
- Promising Phase 3 Results and Future Prospects of Tryngolza Drive Buy Rating for Ionis Pharmaceuticals